Adtalem (ATGE) Q3 2025: Walden Enrollment Jumps 13.5% as Digital Tools Lift Retention

May 8, 2025 | By EarningsIQ Research

Adtalem’s third quarter saw enrollment and margin gains accelerate as digital engagement and program expansion fueled demand across healthcare education segments. Leadership signaled confidence by raising guidance and launching a new buyback, while also highlighting an increasingly favorable regulatory tone. Investors should watch for sustained enrollment strength and operating leverage as new investments ramp into fiscal 2026.

Summary

• Walden’s Digital Engagement Drives Retention: Predictive analytics and student interventions are boosting persistence and fueling enrollment growth.
• Margin Expansion Outpaces Investments: Operating leverage from scale and mix improvement offset new growth spending in most segments.
• Regulatory Backdrop Turns Constructive: Leadership sees a positive policy environment and no sign of student hesitancy around funding.

Performance Analysis

Adtalem delivered broad-based growth in Q3, with consolidated revenue up double digits and strong enrollment momentum across its core healthcare education brands. Walden University, online-focused graduate and undergraduate programs, led the way with a 13.5% enrollment increase—surpassing pre-pandemic levels—driven by digital marketing, predictive analytics, and high conversion rates. Chamberlain University, the largest U.S. nursing school, grew enrollment nearly 7% and continued to expand its online BSN (Bachelor of Science in Nursing) presence, now reaching 36 states and 53 clinical hubs.

Margin expansion was a defining feature, as consolidated adjusted EBITDA margin improved by 150 basis points year over year to 27.4%, and adjusted EPS surged 28%. Walden’s segment margin jumped 650 basis points to 30.3% as operational efficiency outpaced investments in student-facing technology and support. The medical and veterinary segment returned to enrollment growth, but margins declined due to timing of investments and capacity constraints at Ross Vet, which continues to operate near full utilization.

• Enrollment Momentum Broadens: All three reporting segments posted year-over-year enrollment gains, with Walden and Chamberlain the primary drivers.
• Operational Leverage Delivers: Revenue growth and efficiency gains drove higher profitability, even as investments in digital tools and capacity increased.
• Shareholder Returns Accelerate: The $300M buyback program was completed, with a new $150M authorization announced through 2028.

Free cash flow remains robust, supporting both investment and capital returns. Management’s guidance raise reflects confidence in both near-term demand and the ability to balance growth investments with margin expansion.

Executive Commentary

Strategic Positioning

1. Digital Engagement and Predictive Analytics

Walden University’s adoption of predictive analytics, technology that forecasts student outcomes and risk, has materially improved student persistence and retention. Management reports near-record persistence in Walden’s largest programs, directly attributing this to their new engagement platform. This digital-first approach is driving both enrollment and academic outcomes, positioning Walden as a scalable, high-margin growth engine.

2. Portfolio Expansion and Capacity Investments

Chamberlain’s BSN online program, now available in 36 states, and its specialty-focused clinical rotations are broadening Adtalem’s reach into both urban and rural markets. Leadership emphasized ongoing investments to expand program capacity, including potential acquisitions, de novo launches, and geographic expansion. Ross Vet’s near-capacity operation highlights the need for continued investment to unlock further growth.

3. Regulatory Tailwinds and Market Responsiveness

Management described a constructive regulatory environment, with high engagement from the Department of Education and no sign of student funding hesitancy. Adtalem’s career-oriented, healthcare-focused programs are well aligned with both legislative priorities and employer demand, insulating it from some of the sector’s return-on-investment scrutiny.

4. Capital Allocation Discipline

With $763 million returned to shareholders since 2022 and leverage at 0.8x EBITDA, Adtalem is balancing growth investment with capital returns. The new $150 million buyback authorization underscores confidence in long-term free cash flow generation.

Key Considerations

This quarter’s results highlight Adtalem’s ability to combine digital innovation, operational execution, and capital discipline to address critical healthcare workforce shortages. Investors should weigh both the durability of enrollment gains and the margin trajectory as management ramps investment into fiscal 2026.

Key Considerations:

• Digital Transformation at Scale: Predictive analytics and engagement tools are now proven levers for student retention and enrollment growth at Walden.
• Operational Headroom in Core Programs: Chamberlain and Walden still have enrollment runway, but Ross Vet is at capacity, requiring new investment or expansion for further growth.
• Regulatory Risk Mitigated by Program ROI: Adtalem’s focus on high-return, career-oriented healthcare programs positions it well amid evolving federal oversight.
• Margin Expansion Balanced with Growth: Guidance assumes further margin gains even as investment rises, but medical/vet margins will be a watchpoint as spending continues.

Risks

Execution risk around scaling new capacity, particularly in medical and veterinary programs, could constrain growth if not managed proactively. Regulatory changes remain a sector-wide overhang, but Adtalem’s alignment with career and ROI priorities reduces direct exposure. Margin pressure in the medical/vet segment may persist if investments outpace enrollment gains or if capacity expansion lags demand.

Forward Outlook

For Q4, Adtalem expects:

• Increased growth investments to set up for fiscal 2026
• Continued enrollment and revenue momentum across healthcare programs

For full-year 2025, management raised guidance:

• Revenue of $1.76 to $1.775 billion (11-12% YoY growth)
• Adjusted EPS of $6.40 to $6.60 (28-32% YoY growth)
• Adjusted EBITDA margin expansion of >150 basis points, up from prior >100 basis point guidance

Management highlighted:

• Incremental operating leverage from higher revenue
• Planned ramp in growth investments in Q4 to support 2026

Takeaways

Adtalem’s Q3 demonstrated robust enrollment and margin growth, underpinned by digital innovation and disciplined execution. The company is leveraging its scale and market alignment to drive shareholder value, while preparing for a new wave of investment-led growth.

• Digital and operational investments are delivering tangible returns, setting a new baseline for retention and profitability.
• Regulatory and funding risks appear muted, with management citing a supportive policy environment and strong student demand.
• Investors should monitor the pace and impact of new capacity investments, especially in the medical/vet segment, as the company seeks to sustain above-market growth.

Conclusion

Adtalem’s Q3 results confirm that digital innovation and healthcare focus are driving scalable, high-return growth. With raised guidance and a new buyback, management is signaling confidence in both demand and execution, but continued vigilance on investment returns and capacity expansion will be key as fiscal 2026 approaches.

Industry Read-Through

Adtalem’s performance underscores a secular demand tailwind for healthcare education providers, particularly those able to harness digital engagement and analytics for student success. The constructive regulatory tone and focus on career ROI could benefit other education firms with similar market-responsive programs. Capacity constraints in high-demand fields like veterinary medicine signal that scalable, tech-enabled models will have an advantage, while traditional institutions may struggle to keep pace with shifting student and employer needs.

ATGE Consumer Discretionary Education Digital Transformation Healthcare Education Enrollment Margin Expansion Buybacks